흡입형 바이오의약품 시장 규모, 점유율 및 성장 분석 : 제품 유형별, 적응증별, 디바이스 유형별, 최종사용자별, 유통 채널별, 환자 그룹별, 지역별 - 업계 예측(2026-2033년)

Global Inhalable Biologics Market size was valued at USD 612.70 Million in 2024 and is poised to grow from USD 651.30 Million in 2025 to USD 1061.82 Million by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global inhalable biologics market is experiencing significant growth driven by the increasing incidence of chronic respiratory diseases like asthma, COPD, and cystic fibrosis. Innovations in therapeutic proteins, peptides, and nucleic-acid formulations, delivered through nebulizers and dry-powder inhalers, enhance drug concentration at the site of action while minimizing systemic side effects. Advances in protein engineering have led to stable, aerosolizable molecules, exemplified by recent developments in inhalable mRNA vaccines and antibody sprays. Regulatory improvements and evolving reimbursement models are fostering investment, as insurers recognize the cost benefits of targeted pulmonary therapies in reducing hospitalizations. Additionally, advancements in digital inhaler technologies facilitate dose monitoring and adherence, driving further investment and collaboration within the market to tackle the increasing healthcare burden of respiratory diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Inhalable Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Inhalable Biologics Market Segments Analysis

Global inhalable biologics market is segmented by product type, indication, device type, end user, distribution channel, patient group and region. Based on product type, the market is segmented into monoclonal antibodies, peptides & proteins, vaccines and others. Based on indication, the market is segmented into respiratory diseases, infectious diseases, metabolic disorders and others. Based on device type, the market is segmented into dry powder inhalers, nebulizers and metered dose inhalers. Based on end user, the market is segmented into hospitals, home care, specialty clinics and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on patient group, the market is segmented into pediatric, adult and geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Inhalable Biologics Market

The Global Inhalable Biologics market is experiencing significant growth due to the increasing adoption of inhalable formulations by healthcare providers, who are drawn to their ability to deliver targeted therapeutic agents directly to the respiratory system. This targeted approach enhances drug efficacy while minimizing systemic exposure, aligning with the rising trend of precision medicine and fostering acceptance among both physicians and patients. By effectively addressing localized disease mechanisms, inhalable biologics reduce the likelihood of adverse events and improve patient adherence to treatment, further driving market expansion. This heightened focus on personalized therapies is attracting considerable investment from pharmaceutical companies, bolstering the sector's growth potential.

Restraints in the Global Inhalable Biologics Market

The Global Inhalable Biologics market faces significant challenges due to intricate regulatory frameworks that necessitate comprehensive safety, efficacy, and stability data tailored for pulmonary delivery. Regulatory authorities mandate extensive clinical trials to establish consistent dosing and ensure minimal immunogenic risks, which can lead to prolonged development timelines and increased costs. Additionally, the requirement for specialized manufacturing controls adds another layer of complexity to compliance, creating uncertainty for sponsors. As a result, this elevated regulatory burden can discourage investment and impede market entry, ultimately hindering the timely availability of new products for patients and slowing the overall momentum of the market.

Market Trends of the Global Inhalable Biologics Market

The Global Inhalable Biologics market is witnessing a significant trend towards personalized inhalation therapies, where manufacturers are harnessing patient-specific biomarkers and genomics to customize formulations. This approach not only optimizes dosing but also enhances therapeutic outcomes, driving collaboration among biotech firms, diagnostic innovators, and inhalation device manufacturers. By aligning drug design with individual airway physiology, companies can differentiate their product pipelines, improve patient adherence, and minimize adverse events. This shift positions inhalable biologics as a vital component of precision respiratory care, addressing both chronic and acute diseases while supporting overall healthcare sustainability and efficiency initiatives in the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Inhalable Biologics Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies
• Peptides & Proteins
• Vaccines
• Others

Global Inhalable Biologics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Respiratory Diseases
• Infectious Diseases
• Metabolic Disorders
• Others

Global Inhalable Biologics Market Size by Device Type & CAGR (2026-2033)

• Market Overview
• Dry Powder Inhalers
• Nebulizers
• Metered Dose Inhalers

Global Inhalable Biologics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Home Care
• Specialty Clinics
• Others

Global Inhalable Biologics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Inhalable Biologics Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Inhalable Biologics Market Size & CAGR (2026-2033)

• North America (Product Type, Indication, Device Type, End User, Distribution Channel, Patient Group)
  • US
  • Canada
• Europe (Product Type, Indication, Device Type, End User, Distribution Channel, Patient Group)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Device Type, End User, Distribution Channel, Patient Group)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Device Type, End User, Distribution Channel, Patient Group)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Device Type, End User, Distribution Channel, Patient Group)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• MannKind Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerogen Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vectura Group plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AptarGroup, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICONOVO AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resyca BV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phillips-Medisize LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hovione S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations